A Phase 3 interventional study of Renexin (cilostazol 100mg + gingko biloba extract 80 mg) and Placebo in Recurrent Vestibulopathy, sponsored by Jong Woo Chung. Terminated at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-02-17.
Sponsored by Jong Woo Chung · Phase 3, Interventional, and Treatment
The purpose of this study is to determine whether Renexin is effective in the treatment of vestibular symptoms in patients with recurrent vestibulopathy.
Study design
Statistical analysis
34 studies on the registry are indexed under Vestibular Neuronitis; 4 are open to participants now.
This study's enrollment of 26 is below the median of 50 across 27 interventional studies indexed under Vestibular Neuronitis.
Browse Vestibular Neuronitis studies →Jong Woo Chung is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Renexin 1T bid for 12 weeks
Drug: Renexin (cilostazol 100mg + gingko biloba extract 80 mg)
Placebo 1T bid for 12 weeks
Drug: Placebo
Take Renexin 1T bid po medication for 8 weeks
Also known as: Renexin
Take placebo drug 1T bid po medication for 8 weeks
Also known as: Renexin
equilibrium score of dynamic posturography
compared with pretreatment equilibrium score
Time frame: after 8 weeks of treatment
dizziness handicap inventory
compared with pretreatment DHI score
Time frame: at 4 weeks, 8 weeks after treatment
visual analogue scale (VAS) of vertigo
compared with pretreatment VAS score
Time frame: at 4 weeks, 8 weeks after treatment
Questionnaire for Quality of life (SF36)
compared with pretreatment SF36 score
Time frame: at 4 weeks, 8 weeks after treatment
Plan to share: Undecided — This study is decided to be terminated. Among 26 participants, 15 finished medication according to the protocol. I am not sure that these data can be analyzed because data is still unblinded.
No publications or documents are linked to this record.
This study is terminated, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.